Fenofibrate is a PPAR-α agonist that can significantly lower liver stiffness and levels of hyaluronic acid (HA) and transforming growth factor beta 1 (TGF-β1) after 24 weeks of treatment in patients with NAFLD compared to before initiation of treatment. Here, TGFB1 is linked to metabolic dysfunction-associated steatotic liver disease.